UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 (Address of principal executive offices) (Zip Code) Delaware 82-4566526 ☐ TRANSITION REPORT PURSUA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charte ...

Financial Performance - The company has not generated any revenue since inception and does not expect to do so in the foreseeable future[100] - The consolidated net loss for the six months ended June 30, 2022, was $54.0 million, with an accumulated deficit of $197.1 million[93] - The company reported a net loss of $54.0 million for the six months ended June 30, 2022, compared to a net loss of $38.9 million for the same period in 2021[133][134] - The total net decrease in cash, cash equivalents, and restricted cash for the six months ended June 30, 2022, was $85.2 million, compared to a decrease of $197.1 million in 2021[132] - The company experienced a net decrease in working capital of $1.4 million during the six months ended June 30, 2022, primarily due to a decrease in accounts payable and accrued expenses[133] Cash and Investments - As of June 30, 2022, the company had cash and cash equivalents and short-term and long-term investments totaling $279.6 million, excluding $29.4 million at Kinnjiu[92] - The company anticipates that its current cash and cash equivalents will be sufficient to fund operations into early 2024[124] - Net cash used in operating activities for the six months ended June 30, 2022, was $44.6 million, compared to $30.9 million for the same period in 2021, reflecting a consolidated net loss of $54.0 million[133][134] - Net cash used in investing activities during the six months ended June 30, 2022, was $41.3 million, primarily due to purchases of investments totaling $92.5 million, partially offset by sales and maturities totaling $53.7 million[135] - Net cash provided by financing activities for the six months ended June 30, 2022, was $0.8 million, a significant decrease from $35.5 million in the same period in 2021[137][138] Expenses - The company expects significant increases in expenses and capital requirements as it advances its RAF and FGFR programs through clinical development[94] - Research and development expenses increased to $19.8 million for the three months ended June 30, 2022, up from $16.2 million in the same period of 2021, representing a 21.7% increase[114] - For the six months ended June 30, 2022, research and development expenses totaled $39.4 million, compared to $28.9 million in 2021, marking a 36.4% increase[114] - General and administrative expenses rose to $7.6 million for the three months ended June 30, 2022, compared to $5.3 million in 2021, an increase of 43.4%[115] - For the six months ended June 30, 2022, general and administrative expenses were $15.0 million, up from $10.1 million in 2021, reflecting a 48.5% increase[115] Clinical Development - The company initiated the Phase 1 clinical trial KN-8701 for KIN-2787 in May 2021, with dosing beginning in the second half of 2021[85] - KIN-3248, an FGFR inhibitor, received FDA clearance for its IND in January 2022, with the Phase 1 clinical trial initiated in the first quarter of 2022[86] Funding and Capital Requirements - The company has not generated any revenue to date and expects to require substantial additional capital to fund operations and product development[120] - The company completed its IPO on December 7, 2020, raising gross proceeds of $276.0 million from the sale of 13,800,000 shares at $20.00 per share[118] - The company has filed a shelf registration for an at-the-market offering to sell up to $150.0 million of common stock, but no shares have been issued to date[118] - Future funding requirements will depend on various factors, including the costs of clinical development and establishing a sales and marketing infrastructure[125] Operational Risks - The ongoing COVID-19 pandemic may impact the company's business operations and development timelines, with uncertainties remaining[97] - The company relies on third parties for the manufacture of its product candidates and does not own or operate any manufacturing facilities[91] Other Financial Information - Other income, net increased to $0.3 million for the three months ended June 30, 2022, compared to $0.1 million in 2021, a 200% increase[116] - As of June 30, 2022, the company had no debt outstanding, thus eliminating exposure to interest rate risk related to debt[144] - Inflation has not had a material effect on the company's financial results during the periods presented[145] - Foreign currency transaction gains and losses have not been material to the company's financial statements, with a limited number of contracts denominated in foreign currencies[147] - The company had no off-balance sheet arrangements during the periods presented[140]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of Registrant as specified in its Charter) Delaware 82-4566526 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 299-4699 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-39743 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charte ...